Bio-Rad Revenue Up 5 Percent on String Clinical Dx Sales as R&D Spending Hits Profit | GenomeWeb
NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said first-quarter revenues increased 5 percent as R&D spending rose 17 percent and profit fell 13 percent.
 
Total receipts for the three months ended March 31 increased to $322.5 million from $308.3 million year over year.
 
Revenue from the company’s Clinical Diagnostics segment increased nearly 11 percent to $177.6 million, while receipts from the Life Science division slipped 2 percent to $141.6 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.